Beloteca Appoints Dorla Mirejovsky As Chief Scientific Officer

SAN DIEGO, Aug. 24, 2015 /PRNewswire/ -- Beloteca, Inc., a specialty pharmaceutical company focused on the development of sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations, is pleased to announce the appointment of Dorla Mirejovsky, Ph.D. as Chief Scientific Officer.

"We are excited to have Dorla join Beloteca; she is a terrific addition to the team we are building," stated Fred Defesche, Chief Executive Officer of Beloteca, Inc. "Dorla's expertise in developing sterile based pharmaceuticals strengthens the capabilities of Beloteca."

Dr. Mirejovsky brings more than 30 years of pharmaceutical development experience to Beloteca. Dr. Mirejovsky has contributed to the development and commercialization of more than 60 products. She has served in product development roles of increasing responsibility for leading companies such as Allergan, Isis Pharmaceuticals, Sicor Pharmaceuticals, Spectrum Pharmaceuticals and Avrio Biopharma. Dorla joins Beloteca from Avrio Biopharma where she was responsible for the formulation department which supported more than 30 formulation products for various pharmaceutical clients.

"I am very excited to join Beloteca, and look forward to contributing to the development of Beloteca's business," stated Dorla Mirejovsky, Chief Scientific Officer of Beloteca.

Beloteca is a privately held specialty pharmaceutical company. Beloteca's primary focus is to develop and obtain regulatory approval sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. We target niche and difficult to manufacture products. For additional information about the Company, visit the Company's web site at

For further information, please contact Fred Defesche at 512-669-8765 or via email at [email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.